Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.
Zacks.com on MSN19h
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...
Steady M&A Deals to Begin 2025, Disappointing IPOs So Far
Investors rooting for increased M&A and a flurry of IPOs will have to be patient as Q1 tracks with continued low counts on ...
Accumulus Synergy Powers Industry's First Digitally Generated Dossier to Nearly Two Dozen Countries Simultaneously
In an industry-defining moment, Accumulus Synergy ("Accumulus") has powered Amgen's groundbreaking regulatory submission: the first-ever, digitally ...
4AMGN : Amgen Options Trading: A Deep Dive into Market Sentiment
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...
Amgen's Broad Portfolio Strength and Wide Moat Should Protect Profits Despite Upcoming Biosimilars
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...